Diabetes Trials

  1. (194-21) Effect of ziltivekimab in patients with ASCVD and CKD (Phase 3 clinical trial, appropriate for patients with atherosclerotic cardiovascular disease and chronic kidney disease) 
  2. (267-21) Use of the Guardian™ Connect system with Smart Connected Devices (Appropriate for patients with type 1 or type 2 diabetes)
  3. (255-20) A Post Approval Study to Evaluate the Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System Used Nonadjunctively (Post approval study, appropriate for patients with type 1 or type 2 diabetes)